
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dotinurad,Allopurinol
Therapeutic Area : Rheumatology
Study Phase : Phase I/ Phase II
Sponsor : Novo Holdings
Deal Size : $205.0 million
Deal Type : Series A Financing
Novo-Backed Crystalys Debuts With $205M to Tackle Gout
Details : The financing round will support the advancement of Phase 3 evaluating, FYU-981 (dotinurad), a next-generation, once daily oral, URAT1 inhibitor for the treatment of gout.
Product Name : FYU-981
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 30, 2025
Lead Product(s) : Dotinurad,Allopurinol
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Sponsor : Novo Holdings
Deal Size : $205.0 million
Deal Type : Series A Financing
